Blume Capital Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $399K | Sell |
3,160
-35
| -1% | -$4.61K | 0.06% | 102 |
|
|
2026
Q1 | $445K | Hold |
3,195
| – | – | 0.08% | 92 |
|
|
2025
Q4 | $392K | Sell |
3,195
-250
| -7% | -$30.4K | 0.07% | 93 |
|
|
2025
Q3 | $382K | Sell |
3,445
-81
| -2% | -$9.21K | 0.07% | 91 |
|
|
2025
Q2 | $391K | Sell |
3,526
-7
| -0.2% | -$745 | 0.08% | 87 |
|
|
2025
Q1 | $396K | Buy |
3,533
+13
| +0.4% | +$1.34K | 0.09% | 83 |
|
|
2024
Q4 | $325K | Hold |
3,520
| – | – | 0.07% | 89 |
|
|
2024
Q3 | $295K | Hold |
3,520
| – | – | 0.07% | 88 |
|
|
2024
Q2 | $242K | Hold |
3,520
| – | – | 0.06% | 93 |
|
|
2024
Q1 | $258K | Hold |
3,520
| – | – | 0.06% | 89 |
|
|
2023
Q4 | $285K | Sell |
3,520
-80
| -2% | -$6.22K | 0.07% | 81 |
|
|
2023
Q3 | $270K | Sell |
3,600
-2,200
| -38% | -$169K | 0.08% | 81 |
|
|
2023
Q2 | $447K | Hold |
5,800
| – | – | 0.13% | 64 |
|
|
2023
Q1 | $481K | Sell |
5,800
-909
| -14% | -$75.3K | 0.15% | 61 |
|
|
2022
Q4 | $576K | Sell |
6,709
-150
| -2% | -$11.9K | 0.19% | 65 |
|
|
2022
Q3 | $423K | Buy |
6,859
+189
| +3% | +$11.9K | 0.16% | 58 |
|
|
2022
Q2 | $412K | Buy |
6,670
+1,091
| +20% | +$67.5K | 0.16% | 58 |
|
|
2022
Q1 | $332K | Buy |
5,579
+2,000
| +56% | +$128K | 0.11% | 61 |
|
|
2021
Q4 | $260K | Buy |
3,579
+120
| +3% | +$8.27K | 0.09% | 81 |
|
|
2021
Q3 | $242K | Sell |
3,459
-300
| -8% | -$21.1K | 0.09% | 78 |
|
|
2021
Q2 | $259K | Sell |
3,759
-100
| -3% | -$6.68K | 0.09% | 74 |
|
|
2021
Q1 | $249K | Buy |
3,859
+709
| +23% | +$45.7K | 0.1% | 70 |
|
|
2020
Q4 | $184K | Sell |
3,150
-200
| -6% | -$12.1K | 0.08% | 68 |
|
|
2020
Q3 | $212K | Hold |
3,350
| – | – | 0.11% | 58 |
|
|
2020
Q2 | $258K | Hold |
3,350
| – | – | 0.14% | 53 |
|
|
2020
Q1 | $250K | Sell |
3,350
-165
| -5% | -$11.4K | 0.16% | 49 |
|
|
2019
Q4 | $228K | Sell |
3,515
-100
| -3% | -$6.51K | 0.11% | 61 |
|
|
2019
Q3 | $229K | Hold |
3,615
| – | – | 0.11% | 61 |
|
|
2019
Q2 | $244K | Buy |
3,615
+165
| +5% | +$10.9K | 0.12% | 60 |
|
|
2019
Q1 | $224K | Hold |
3,450
| – | – | 0.12% | 67 |
|
|
2018
Q4 | $216K | Sell |
3,450
-100
| -3% | -$6.99K | 0.12% | 68 |
|
|
2018
Q3 | $274K | Hold |
3,550
| – | – | 0.14% | 54 |
|
|
2018
Q2 | $251K | Hold |
3,550
| – | – | 0.14% | 55 |
|
|
2018
Q1 | $267K | Sell |
3,550
-700
| -16% | -$55.6K | 0.15% | 54 |
|
|
2017
Q4 | $304K | Sell |
4,250
-450
| -10% | -$34.2K | 0.16% | 54 |
|
|
2017
Q3 | $381K | Buy |
4,700
+200
| +4% | +$15.3K | 0.2% | 47 |
|
|
2017
Q2 | $319K | Sell |
4,500
-850
| -16% | -$56.6K | 0.18% | 47 |
|
|
2017
Q1 | $363K | Buy |
5,350
+550
| +11% | +$38.7K | 0.21% | 41 |
|
|
2016
Q4 | $344K | Sell |
4,800
-1,050
| -18% | -$78K | 0.21% | 41 |
|
|
2016
Q3 | $463K | Buy |
5,850
+350
| +6% | +$28.4K | 0.28% | 37 |
|
|
2016
Q2 | $459K | Buy |
5,500
+50
| +0.9% | +$4.44K | 0.3% | 39 |
|
|
2016
Q1 | $501K | Buy |
5,450
+400
| +8% | +$36.1K | 0.35% | 39 |
|
|
2015
Q4 | $511K | Sell |
5,050
-1,400
| -22% | -$146K | 0.36% | 40 |
|
|
2015
Q3 | $633K | Sell |
6,450
-46
| -0.7% | -$5.11K | 0.51% | 32 |
|
|
2015
Q2 | $761K | Sell |
6,496
-17,313
| -73% | -$1.89M | 0.58% | 32 |
|
|
2015
Q1 | $2.34M | Buy |
23,809
+18,619
| +359% | +$1.89M | 1.62% | 24 |
|
|
2014
Q4 | $489K | Buy |
5,190
+290
| +6% | +$30K | 0.34% | 38 |
|
|
2014
Q3 | $522K | Hold |
4,900
| – | – | 0.41% | 38 |
|
|
2014
Q2 | $406K | Hold |
4,900
| – | – | 0.32% | 39 |
|
|
2014
Q1 | $347K | Sell |
4,900
-500
| -9% | -$39.2K | 0.28% | 41 |
|
|
2013
Q4 | $406K | Buy |
+5,400
| New | +$376K | 0.34% | 39 |
|
Other funds holding GILD
Blume Capital Management's GILD Position: Q2 2026 in Review
Blume Capital Management reduced its Gilead Sciences (GILD) stake by 1.1% in Q2 2026, selling an estimated $4.61K and leaving 3,160 shares worth $399K. The position accounts for 0.06% of the portfolio, ranked #102.
Blume Capital Management first reported a position in GILD in Q4 2013 and has held it in 51 quarters since. The position peaked at $2.34M in Q1 2015. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Blume Capital Management held 3,160 shares of Gilead Sciences worth $399K as of Q2 2026.
- Blume Capital Management sold 35 Gilead Sciences shares in Q2 2026, an estimated $4.61K.
- Gilead Sciences made up 0.06% of Blume Capital Management's portfolio in Q2 2026, its #102 holding.
- Blume Capital Management first reported a position in Gilead Sciences in Q4 2013 and has held it in 51 quarters since.
- Blume Capital Management's Gilead Sciences position peaked at $2.34M in Q1 2015.
- 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.